MedTrace Logo

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

NCT01717027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-08-31

No results posted yet for this study

Summary

To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of PF-00345439 formulations taken whole under fed conditions and after chewing under fasted conditions in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions

Sponsors & Collaborators

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717027 on ClinicalTrials.gov